| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8815109 | Journal of Affective Disorders | 2018 | 6 Pages |
Abstract
CHRNA7 gains are relatively prevalent among young individuals with MDD and anxiety disorders (odds ratioâ¯=â¯4.032) without apparent distinguishing clinical features. Future studies should examine the therapeutic potential of α7 nAChR targeting drugs to ameliorate depressive and anxiety disorders.
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
Madelyn A. Gillentine, Ricardo Lozoya, Jiani Yin, Christopher M. Grochowski, Janson J. White, Christian P. Schaaf, Chadi A. Calarge,